GlassScriptPhysician profile
Zachary James Geiling
NPI 1851045223
$3,041.87
in general payments reported to CMS, 2019-2025
21 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $593 · 2024: $990 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.45 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.01 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $433.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Vertex Pharmaceuticals Incorporated | $294.40 | 2025 | |
| Glaxosmithkline, LLC. | $232.28 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $171.63 | 2025 | |
| Phathom Pharmaceuticals, INC. | $124.80 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $122.88 | 2022 | |
| Viiv Healthcare Company | $120.58 | 2023 | Dovato |
| Gilead Sciences, INC. | $112.80 | 2023 | Biktarvy |
| Lilly USA, LLC | $104.35 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.50 | 2024-2025 | Caplyta |
| Pfizer INC. | $49.95 | 2025 | |
| Antares Pharma, INC. | $30.64 | 2024-2025 | Xyosted |
| Boston Scientific Corporation | $30.23 | 2025 | Wavewriter Alpha Prime 16 |
| Baxter Healthcare | $27.21 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $26.07 | 2024 | Aquabeam System |
| Otsuka America Pharmaceutical, INC. | $22.25 | 2023 | Rexulti, Abilify Maintena |
| Verona Pharma, INC. | $18.19 | 2025 | Ohtuvayre |
| Halozyme INC | $17.76 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $15.75 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Geiling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.